Okay, so today I’d like to discuss who needs chemotherapy with immunotherapy actually in the luminal type breast cancer. In general, luminal type breast cancer nowadays is treated by upfront surgery and doing chemotherapy after that. But for doing immunotherapeutic checkpoint inhibitor, we need to do a neoadjuvant therapy with immunochemotherapy. Today, there are two completed phase 3 studies, which are CheckMate 7FL and KEYNOTE-522...
Okay, so today I’d like to discuss who needs chemotherapy with immunotherapy actually in the luminal type breast cancer. In general, luminal type breast cancer nowadays is treated by upfront surgery and doing chemotherapy after that. But for doing immunotherapeutic checkpoint inhibitor, we need to do a neoadjuvant therapy with immunochemotherapy. Today, there are two completed phase 3 studies, which are CheckMate 7FL and KEYNOTE-522. And both have a pCR increase by adding immunotherapeutic checkpoint inhibitor. In KEYNOTE-756, it increased 8.5%. And in the KEYNOTE-522 study, it increased about 10% by adding immunotherapeutic checkpoint inhibitor. But we don’t have yet the result of eventual survival. So at this moment, we don’t have any chance of using our ICI in the early breast cancer setting, but probably we need to titrate the patient who has more benefit from immune checkpoint inhibitor, that is ER low expression or PD-L1 positive, and there are other kinds of margin assays which are MammaPrint or MP2 or Oncotype DX positive tumor. So this kind of more titrated patient may have a benefit by PD-1 inhibitor, but it’s not established yet.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.